Kyndryl Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $15B-0.6% YoYTTM through 30 Jun 2026
Net Income $87M-65.5% YoYTTM through 30 Jun 2026
Free Cash Flow $148MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 6.9% |
| Operating Margin | 1.7% |
| Net Margin | 0.6% |
Returns
8.1%ROE
0.7%ROA
1.9%ROIC
Balance Sheet Health
Debt / Equity5.31x
Current Ratio0.85x
Net Debt$3.6B
Cash & Equivalents$2.1B
Quality Metrics
Altman Z-Score1.14
Piotroski F-Score5 / 9
FCF Margin1.0%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2026: $15.1B
Diluted EPS$0.37TTMFY2026: $0.85
Dividend
No dividend
Capital Allocation
R&D Spend$57M
Capex Intensity4.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| United States | |||
| Japan | |||
| Principal Markets | |||
| Strategic Markets |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.